Although the role in oncogenesis of FGFR3 fusion proteins caused by translocations in multiple myeloma has not been entirely resolved [2], it is interesting that these tumors have been associated with increased cyclin D1 [47, 48], and that HDAC inhibitors have been found to have some therapeutic benefit in multiple myeloma. The gene discussed is FGFR3; the disease is AL amyloidosis.